A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

被引：0
作者：
Hiroyuki Uetake
Masamichi Yasuno
Megumi Ishiguro
Shingo Kameoka
Yasuhiro Shimada
Keiichi Takahashi
Toshiaki Watanabe
Kei Muro
Hideo Baba
Junji Yamamoto
Nobuyuki Mizunuma
Hiroshi Tamagawa
Izumi Mochizuki
Yusuke Kinugasa
Takashi Kikuchi
Kenichi Sugihara
机构：
[1] Tokyo Medical and Dental University,Department of Translational Oncology, Graduate School
[2] Tokyo Metropolitan Hiroo Hospital,Department of Surgery
[3] Tokyo Women’s Medical University,Department of Surgery II
[4] National Cancer Center Hospital,Division of Gastrointestinal Medical Oncology
[5] Tokyo Metropolitan Cancer and Infectious Disease Center,Colorectal Surgical Division, Department of Surgery
[6] Komagome Hospital,Department of Surgical Oncology, Graduate School of Medicine
[7] The University of Tokyo,Clinical Oncology
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery, Graduate School of Medical Science
[9] Kumamoto University,Department of Surgery
[10] National Defense Medical College,Gastroenterological Center
[11] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[12] Osaka General Medical Center,Department of Surgery
[13] Iwate Prefectural Central Hospital,Gastrointestinal Surgery Division
[14] Shizuoka Cancer Center,Department of Statistical Analysis
[15] Translational Research Informatics Center,Department of Surgery Oncology
[16] Tokyo Medical and Dental University,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Bevacizumab; Liver Metastasis; Sixth Cycle; Resectable Liver Metastasis; High Adverse Event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：908 / 915
页数：7
相关论文
共 35 条
  • [21] A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
    Bendell, Johanna C.
    Zakari, Ahmed
    Peyton, James D.
    Boccia, Ralph
    Moskowitz, Mark
    Gian, Victor
    Lipman, Andrew
    Waterhouse, David
    LoCicero, Richard
    Earwood, Chris
    Lane, Cassie M.
    Meluch, Anthony
    ONCOLOGIST, 2016, 21 (03) : 279 - 280
  • [22] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
    Li, Sheng
    Li, Xiaoyou
    Zhu, Qianni
    Gao, Jin
    Zhu, Chunrong
    Zhu, Liangjun
    CANCER CONTROL, 2024, 31
  • [23] Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
    Oki, Eiji
    Makiyama, Akitaka
    Miyamoto, Yuji
    Kotaka, Masahiko
    Kawanaka, Hirofumi
    Miwa, Keisuke
    Kabashima, Akira
    Noguchi, Tomohiro
    Yuge, Kotaro
    Kashiwada, Tomomi
    Ando, Koji
    Shimokawa, Mototsugu
    Saeki, Hiroshi
    Akagi, Yoshito
    Baba, Hideo
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER MEDICINE, 2021, 10 (02): : 454 - 461
  • [24] A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
    Feng, Ai-Wei
    Guo, Jian-Hai
    Gao, Song
    Kou, Fu-Xin
    Liu, Shao-Xing
    Liu, Peng
    Chen, Hui
    Wang, Xiao-Dong
    Xu, Hai-Feng
    Cao, Guang
    Zhu, Xu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial
    Ychou, Marc
    Rivoire, Michel
    Thezenas, Simon
    Guimbaud, Rosine
    Ghiringhelli, Francois
    Mercier-Blas, Anne
    Mineur, Laurent
    Francois, Eric
    Khemissa, Faiza
    Chauvenet, Marion
    Kianmanesh, Reza
    Fonck, Marianne
    Houyau, Philippe
    Aparicio, Thomas
    Galais, Marie-Pierre
    Audemar, Franck
    Assenat, Eric
    Lopez-Crapez, Evelyne
    Jouffroy, Claire
    Adenis, Antoine
    Adam, Rene
    Bouche, Olivier
    BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1264 - 1270
  • [26] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Nikol Snoeren
    Emile E Voest
    Andre M Bergman
    Otilia Dalesio
    Henk M Verheul
    Rob AEM Tollenaar
    Joost RM van der Sijp
    Sander B Schouten
    Inne HM Borel Rinkes
    R van Hillegersberg
    BMC Cancer, 10
  • [27] Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer
    Stefan Madajewicz
    David M. Waterhouse
    Paul S. Ritch
    M. Qaseem Khan
    Donald J. Higby
    Cynthia G. Leichman
    Sandeep K. Malik
    Patricia Hentschel
    John F. Gill
    Luping Zhao
    Steven J. Nicol
    Investigational New Drugs, 2012, 30 : 772 - 778
  • [28] Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer
    Madajewicz, Stefan
    Waterhouse, David M.
    Ritch, Paul S.
    Khan, M. Qaseem
    Higby, Donald J.
    Leichman, Cynthia G.
    Malik, Sandeep K.
    Hentschel, Patricia
    Gill, John F.
    Zhao, Luping
    Nicol, Steven J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 772 - 778
  • [29] Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)
    Oki, Eiji
    Emi, Yasunori
    Miyamoto, Yuji
    Kabashima, Akira
    Higashi, Hidefumi
    Ogata, Yutaka
    Ikebe, Masahiko
    Saeki, Hiroshi
    Tokunaga, Shoji
    Shirabe, Ken
    Beppu, Toru
    Uchida, Shinji
    Takatsuki, Mitsuhisa
    Sakoda, Masahiko
    Eguchi, Susumu
    Akagi, Yoshito
    Kakeji, Yoshihiro
    Baba, Hideo
    Natsugoe, Shoji
    Maehara, Yoshihiko
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S1067 - S1074
  • [30] Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)
    Eiji Oki
    Yasunori Emi
    Yuji Miyamoto
    Akira Kabashima
    Hidefumi Higashi
    Yutaka Ogata
    Masahiko Ikebe
    Hiroshi Saeki
    Shoji Tokunaga
    Ken Shirabe
    Toru Beppu
    Shinji Uchida
    Mitsuhisa Takatsuki
    Masahiko Sakoda
    Susumu Eguchi
    Yoshito Akagi
    Yoshihiro Kakeji
    Hideo Baba
    Shoji Natsugoe
    Yoshihiko Maehara
    Annals of Surgical Oncology, 2015, 22 : 1067 - 1074
1234